ClinicalTrials.gg
RecruitingNCT07375355ASC4CNUpdated Apr 1, 2026

Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China

An observational study in Chronic Myeloid Leukemia in Chronic Phase, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis — 9 open to participants now, 13 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Novartis.

Planned enrollment
14th of 19
200 · median 400
Started
2026
with 3 others
Observational
19 of 92
6 open now
Primary completion
2028-12
later than 7 of 12 live
Registered
89th of 92
by date

Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 14th largest by planned enrollment of the 19 observational ones that give a count, is one of 4 that started in 2026, is one of 19 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 89th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

9 of the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, or all of them as a file.
02

Study summary

This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.

03

Conditions studied

  • Chronic Myeloid Leukemia in Chronic Phase

Keywords

  • CML-CP
  • Asciminib
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients newly diagnosed with CML-CP and confirmed with Ph+ CML in medical records

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in this study must meet all the following criteria:

  1. 18 years or older at the time of ICF signing;
  2. Newly diagnosed with Ph+ CML-CP within 3 months before enrollment;

    - The diagnosis documentation must include the type and quantitative level of the BCR-ABL1 transcript.

  3. Prior treatment with a maximum of 2 weeks of TKIs;
  4. Prior treatment with non-TKI regimens, including interferon and hydroxyurea, is allowed;
  5. Patients scheduled to initiate treatment with asciminib;

    - Patients beginning asciminib treatment must receive the first dose within 14 days of signing the ICF;

  6. Signed ICF.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria are not eligible for inclusion in this study:

  1. Previous diagnosis of CML-accelerated phase or blast crisis;
  2. Currently participating in an interventional clinical study for CML;
  3. Having rare, atypical transcript types that cannot be standardised internationally;
  4. Women who are pregnant, lactating or planning to become pregnant during the study;
  5. Concurrent other (refer to the International ICD-11 diagnosis codes, with diagnostic text including carcinoma, malignant neoplasm, etc.);
  6. Other conditions that are considered not suitable for the study by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study Group

    Asciminib treatment

06

What researchers measure

Primary outcomes

  1. Cumulative rate of MMR

    Cumulative rate of major molecular response (MMR) (BCR-ABL1 transcript level ≤ 0.1%) in patients receiving asciminib for 12 months

    Time frame: Month 12

Secondary outcomes

  1. Cumulative rate of MMR

    The cumulative MMR is defined as at least one BCR::ABL1 transcript level ≤ 0.1% during the follow-up period

    Time frame: Month 3, Month 6, Month 9, Month 18 and Month 24

  2. Cumulative rate of deep molecular response (DMR): MR4 and MR4.5

    Cumulative rate of MR4 is defined as at least one BCR::ABL1 transcript level ≤ 0.01% during the follow-up period; Cumulative MR4.5 is defined as at least one BCR::ABL1 transcript level ≤0.0032% during the follow-up period

    Time frame: Month 3, Month 6, Month 9, Month 12, Month 18, and Month 24

  3. Cumulative rate of complete cytogenetic response (CCyR)

    Cumulative CCyR is defined as at least one cytogenetic examination showing 0 Ph+ cells during the follow-up period

    Time frame: Month 3, Month 6, and Month 12

  4. Time to first MMR

    Time to first MMR is defined as the time interval from baseline to the first occurrence of BCR::ABL1 transcript level ≤0.1% during the follow-up period

    Time frame: 24 month follow up period

  5. Time to first MR4 and MR4.5

    Time to first MR4 is defined as the time interval from baseline to the first occurrence of BCR::ABL1 transcript level ≤0.01% during the follow-up period. Time to first MR4 is defined as the time interval from baseline to the first occurrence of BCR::ABL1 transcript level ≤0.0032% during the follow-up period

    Time frame: 24 month follow up period

  6. Time to first complete cytogenetic response (CCyR)

    Time to first CCyR is defined as the time interval from baseline to the first occurrence of CCyRduring the follow-up period

    Time frame: 24 month follow up period

  7. Early molecular response (EMR) rate at 3 months

    Proportion of patients achieving BCR::ABL1 transcript level ≤10% at M3

    Time frame: Month 3

  8. Complete hematologic response (CHR) rate

    the proportion of patients achieving white blood cell count \< 10 × 109/L, platelet count \< 450 × 109/L, no immature myeloid cells in peripheral blood, peripheral blood basophil percentage \< 5%, absence of symptoms/signs of extramedullary involvement, and non-palpable spleen at M1, M2, and M3

    Time frame: Month 1, Month 2, and Month 3

  9. Rate of decline in BCR::ABL1 transcript levels

    indirectly calculated from BCR::ABL1 transcript levels at baseline, M1, M2, M3, M6, M9, and M12; determined by BCR::ABL1 halving time

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 6, Month 9 and Month 12

  10. Duration of MMR

    Definition of duration: Duration = sum of "intervals"; Interval calculation method: the first visit at which a response is achieved (and previously unmeasured) within the interval is taken as the starting point, then evaluated sequentially in time order; the calculation stops upon encountering a visit that fails to meet the criterion; The duration is calculated as the time interval between the first and last visit at which the response was achieved; Missing visit data points during this period will be defaulted as achieving the response.

    Time frame: 24 month follow up period

  11. Duration of MR4 and MR4.5

    Time frame: 24 month follow-up period

  12. Event-Free survival (EFS) rate

    Lack of efficacy: * Failure to achieve expected molecular response: failure to reach the molecular response milestones recommended by the ELN guidelines at prespecified time points; * Loss of molecular response: loss of confirmed MMR following achievement of MMR, or loss of CCyR. Disease progression: progression from the chronic phase to the accelerated phase or blast crisis. Death: fatal outcome due to any cause during the treatment period. Treatment discontinuation due to adverse events: permanent discontinuation caused by intolerable toxicity, serious adverse events, or other safety-related reasons associated with the study drug.

    Time frame: Month 12 and Month 24

  13. Progression-free survival (PFS) rate

    Time frame: Month 12 and Month 24

  14. Overall survival (OS) rate

    Time frame: Month 12 and Month 24

  15. Adverse events (AEs) and serious adverse events (SAEs) occurring during asciminib treatment

    Time frame: 24 month follow-up period

  16. Asciminib persistence rates

    Time frame: Month 6, Month 12, and Month 24

  17. Rates of asciminib treatment interruption/dose reduction and discontinuation due to AEs

    Time frame: 24 month follow-up period

  18. Proportion of patients requiring concomitant medications due to AEs

    Time frame: 24 month follow-up period

  19. Change in the simplified CML quality of life questionnaire from baseline

    Time frame: Baseline, Month 12 and Month 24

  20. Compliance following asciminib treatment

    Medication possession ratio

    Time frame: 24 month follow-up period

  21. Concomitant medication use associated with AEs related to asciminib

    Time frame: 24 month follow-up period

  22. Hospitalization rate, outpatient visit rate, emergency department visit rate, and ICU admission rate related to CML treatment

    Time frame: 24 month follow-up period

  23. Gene mutation rate associated with asciminib treatment

    Gene mutation rate associated with asciminib treatment; types and proportions of positive gene mutations identified via genetic testing.

    Time frame: 24 month follow-up period

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 29, 2026
StartActual
Feb 12, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07375355
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Feb 12, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 1, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion